aTyr Pharma (NASDAQ:LIFE) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of aTyr Pharma (NASDAQ:LIFE) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

LIFE has been the subject of several other research reports. Royal Bank of Canada cut their price target on aTyr Pharma from $19.00 to $16.00 and set an outperform rating for the company in a report on Friday, March 15th. HC Wainwright restated a buy rating and set a $35.00 price target on shares of aTyr Pharma in a report on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Hold and an average target price of $23.67.

aTyr Pharma Stock Up 2.7 %

Shares of LIFE opened at $1.90 on Friday. The company has a market capitalization of $131.12 million, a PE ratio of -2.11 and a beta of 1.19. The business’s 50 day moving average is $1.76 and its 200 day moving average is $1.67. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02. aTyr Pharma has a 12-month low of $1.08 and a 12-month high of $2.45.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.11 million. Research analysts expect that aTyr Pharma will post -0.89 earnings per share for the current fiscal year.

Insider Transactions at aTyr Pharma

In related news, Director Timothy Coughlin bought 50,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was purchased at an average price of $1.75 per share, for a total transaction of $87,500.00. Following the acquisition, the director now owns 56,000 shares in the company, valued at $98,000. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In other aTyr Pharma news, CEO Sanjay Shukla acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The stock was bought at an average price of $1.81 per share, for a total transaction of $36,200.00. Following the acquisition, the chief executive officer now directly owns 136,548 shares in the company, valued at $247,151.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Timothy Coughlin acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The shares were acquired at an average price of $1.75 per share, with a total value of $87,500.00. Following the acquisition, the director now owns 56,000 shares in the company, valued at $98,000. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 75,000 shares of company stock worth $132,650. 3.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On aTyr Pharma

A number of large investors have recently bought and sold shares of LIFE. Granite Bay Wealth Management LLC bought a new stake in aTyr Pharma during the 4th quarter valued at $25,000. SG Americas Securities LLC bought a new stake in aTyr Pharma during the 1st quarter valued at $55,000. Acadian Asset Management LLC raised its position in aTyr Pharma by 119.6% during the 1st quarter. Acadian Asset Management LLC now owns 45,366 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 24,704 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new stake in aTyr Pharma during the 1st quarter valued at $117,000. Finally, Pale Fire Capital SE raised its position in aTyr Pharma by 425.8% during the 4th quarter. Pale Fire Capital SE now owns 293,706 shares of the biotechnology company’s stock valued at $414,000 after purchasing an additional 237,849 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.